Tofacitinib

Creative Commons License

Şentürk N.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, ss.67-69, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4274/turkderm.galenos.2022.64715
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.67-69
  • Anahtar Kelimeler: Psoriasis, tofacitinib, JAK inhibitor, JANUS KINASE INHIBITOR, SEVERE PLAQUE PSORIASIS, MODERATE, EFFICACY, SAFETY
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical studies. A 10 mg daily dose has been observed to achieve a PASI75 response in 40-64% of the patients with moderate to severe psoriasis at week 12 or 16. It provides advantage in the treatment of psoriasis due to oral use, lower cost compared to other biologics, and absence of organ toxicity.